Vaxil Bio Ltd. (TSXV:VXL)

Canada flag Canada · Delayed Price · Currency is CAD
0.1600
0.00 (0.00%)
At close: Aug 18, 2025
Market Cap438.33K
Revenue (ttm)n/a
Net Income (ttm)-190.00K
Shares Out2.74M
EPS (ttm)-0.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,832
Average Volume2,088
Open0.1600
Previous Close0.1600
Day's Range0.1600 - 0.1600
52-Week Range0.1600 - 0.3250
Beta-1.79
RSI31.68
Earnings DateAug 27, 2025

About Vaxil Bio

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol VXL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.